The tumoral immunoreactivity of α-SMA was significantly expressed (p = 0.047) in all BCC variants, and patients with infiltrative BCC had a higher mean (2.57 ± 0.35) compared to other BCC variants. This evidence concerns the gene ACTA1 and skin basal cell carcinoma.